10 Best Organ Transplant and Diagnosis Stocks To Buy Now

3. Becton, Dickinson and Company (NYSE:BDX)

Market Cap as of August 1: $68.22 Billion

Hedge Funds Holding Stakes: 60

Becton, Dickinson and Company (NYSE:BDX) is a medical instruments company that designs and develops medical supplies, devices, and laboratory equipment, some of which are of great use in the organ transplant industry. With a history of pioneering work and significant accomplishments like the Vacationer system for collecting blood and automated systems for culturing blood, Becton, Dickinson and Company (NYSE:BDX) remains at the forefront of healthcare progress by conducting advanced research and development.

Its dedication to enhancing patient results, environmental sustainability, and ethical practices distinguishes it in the market, doubling as a reliable collaborator for medical institutions around the globe. Becton, Dickinson and Company (NYSE:BDX) generated $19.4 billion in sales in 2023, which was up 2.7% year over year. The stock is down by about 2.4% for the year. The number of hedge funds owning stakes in the company remained flat at 60 as of the end of Q1 2024 according to Insider Monkey database.

Here is what Madison Investors Fund said about Becton, Dickinson and Company (NYSE:BDX) in its Q2 2024 investor letter:

“During the quarter, we sold our stake in Becton, Dickinson and Company (NYSE:BDX). Becton is a leading global medical technology and diagnostics company. We admire its dominant market position spanning a vast array of consumable medical products. However, in more recent years, the company has pursued a capital allocation strategy focused a bit more on acquisitions than we’d prefer, and has had operational hiccups in some product lines and geographies. While we believe the company will manage through the issues, we decided to sell to fund more attractive opportunities.”